# Asco-GU 2018 San Francisco

#### Maurizio Brausi







DEPARTMENT OF UROLOGY Carpi - Modena , ITALY

#### **ASCO-GU 2018 : Bladder Cancer Program**

- 2 General Sessions:
  - \* Current and future directions of MIBC : 4 lectures + 1 selected abstract
  - \* Multimodality approach to locally advanced BC : 3 lectures (case discussion) + 1 selected abstract
- 2 Keynote lectures
- Poster Sections: 139 posters
  - . 9 UUT Tcc
  - . 17 NMIBC
  - . 113 MIBC
- 2 Symposia



**Immunotherapy in Bladder Cancer : Asco-GU 2018** 

- Immunotherapy in NMIBC: State of the art and new developments R Colombo
- Debater/opinion leader Bassi
- Clinical case (Brausi) with Colombo and Bassi + audience



# **Urothelial TCC of Upper Urinary Tract**

- Treatment of High risk and muscle invasive TCC of UUT: The role on neo-adiuvant and adjuvant chemotherapy after the new data from ASCO-GU 2018 **POUT** study Necchi
- Debater: Bassi



Carpi - Modena , ITALY

### **Muscle Invasive Bladder Cancer**

- **Bladder Sparing procedures:** State of the art and Asco-Gu news Brausi
- Discussant: Bassi
- Clinical case (Colombo): Bassi, Brausi, Necchi + Audience
- *Immunotherapy in MIBC*: Agents and available + new Trials A.Necchi Discussion with panel and audience
- The Future in MIBC: Genomic Atlas : Brausi





### •Have a Nice Discussion !!!



Maurizio A Brausi

- LE 73 yr, smoker (15 sig./day since 30 yrs) 09.'96 disuria, urge and one episode of macro-hematuria.
- Cytology positive
   US: lesion of 1.6 cm in the L lat. bladder wall Prostate: 4.5 x4.8 cm. No nodules. Psa = 3.5 ng/ml
- O9.96 Urethrocystoscopy (anest.): 1 papillary lesion in the L lat. wall of 1.5cm + 2 lesions of 0.5 and 0.4 cm in the post wall and left trigone. No other suspicious areas
   Treatment: TUR of the lesions + deep biopsy of tumor bed. Fulguration of surrounding areas (1-2 cm)





• Path Report:

1. Transitional cell carcinoma grade 2 confined to the mucosa. No infiltration of lamina propria. Muscle present with no infiltration.


- 2 and 3 TCC confined to the mucosa
- Staging: Primary multiple TaG2

- 10.96 Pat. randomized in EORTC prot. 30911 (Epi vs BCG vs BCG +INH).
   Epi 50 mg x 6 with maintenance 3 years.
   F-Up: No side effects. No recurrence (Cyto + Cysto: neg)
- 04.2006 Disuria, UTI, nocturia (4) I-PSS 18.
  3 cytology : displasia. Psa = 3.7ng/ml
- **US:** Enlarged prostate x3. No nodules or firm areas. Suspicious lesion on the R wall. Cytology : +
- Flexible uretro-cystoscopy: stenosis (13F) of bulbous urethra. Prostate of 4.7 x 5 cm.
   2 small papillary lesions on the Discup wall 1 and 0.8


2 small papillary lesions on the R+ sup. wall 1 and 0.8 c



• *10.06* Uro- CT = Negative



- **11.06** TUR of the 2 lesions and bladder mapping according to Eortc (7 biopsies).
- Path Report. Ta G2 + Cis in 1 fragment (L lat wall).
- 12.07 BCG x 6 with maintenance (3 years). After 4 instillations patient (83 yr) had severe disuria, macroscopic hematuria, fever > 38°.
   He wanted to stop BCG.



- 02.07 MMC + EMDA x 6 with maintenance, once a month for 12 months
- 06.07 Local side effects : disuria and burning Cytology : mild dysplasia . Cysto: Negative Bladder capacity reduced (< 150cc)</li>
- 10.07 Cytology: Neg Cystoscopy (No anesthesia) : red velvet areas on the L trigone and post. wall: cold cup biopsies
- Path Report: mild dysplasia + inflammation

- 02.08 UTI treated with chinolones.
   Disuria with nocturia >5. Urge incontinence (2 pads/day)
- Cytology: neg. Cystoscopy: urethal stenosis (13F) reduced bladder capacity (100cc) with enlarged prostate (Dutasteride + Tamsulosin).
- 04.08 Uro-CT: thikness of the bladder wall with R hydro (Grade 1). No bladder or metastatic lesions
- O8.08 Stable. Cytology and cysto negative. UTI cured by antibiotics. QoL really affected.....

### Comments

- Should we treat these patients more aggressively after recurrence ?
- How can we improve their quality of life ?
- Is radical cystectomy an option ?
- Is an enlarged prostate a contra-indication for BCG? (UTI)
- Age: is it important for deciding between immuno and chemo?

# **Bladder Sparing Approach to MIBC**

• ASCO-GU 2018

• Maurizio Brausi



DEPARTMENT OF UROLOGY Carpi - Modena , ITALY

#### **Bladder Preservation: Goals**

Avoid major surgery (death rate 0-7%)
 Obtain favorable oncological outcome
 Maintain physiological voiding
 Preserve potency (QoL)
 Preserve ejaculation and fertility



#### **Risk of Bladder Sparing Strategies**

A delay in RC increases the risk of lymphnode metastases

Nodes positive rate of 26% when RC becomes necessary because of treatment failure vs 15% when RC is perfomed immediately (EUA Guideline 2008)



### **Strategies for Bladder Preservation: History**

#### Neoadjuvant Chemo + Tur + Re-staging Tur



EPARTMENT OF UROLOGY Carpi - Modena , ITALY

### **MSKCC Experience : 10 yr FU**

N Pts. = 111 received neo-adjuvant M-Vac + TUR PT0 = 60/111 ( 54%) The majority of them had long term survival with k

The majority of them had long term survival with bladder preservation (Herr et al: J Clin. Onc. '98)



#### **Chemo For Bladder Preservation**

Neo-adjuvant M-Vac in cT2-T4 N0M0 BC N Pts. = 104 treated with TUR after M-Vac Results: 49/104 (49%) were T0. Responding pts underwent Re-Tur or Partial C Median Survival = 7.5 yrs 60% of pts. (M-Vac+ TUR) are alive at mean F-Up of 56 mo.

44% of pts. treated with TUR alone maintained their bladder

EPARTMENT OF UROLOGY Carpi - Modena, ITALY

(Sternberg et al Cancer '03)

#### **MSKCC Experience** (Herr, Eur Urol 2008)

N pts. = 63 (decline to recive RC) for PT0 after Cis-Platin based chemo + TUR Results: (median F-up = 86 mo) 40/63 (64%) survived : 54% of them maintained their bladder

The most significant treatment variable predicting better survival was: **pTO on Re-staging TUR before starting chemotherapy** 



#### **MSKCC Experience**

#### **Results**

23/63 pts (36%) died of disease

19/63 relapsed with MIBC

Over 90% of surviving pts. had solitary, small, low stage (pT2) invasive tumours completely resected

83% of them survived with no relapse

(Herr Eur Urol 2008)



TURBT and twice-daily RT + paclitaxel-cisplatin or fluorouracilcisplatin with selective BP and A- chemo for pts. with MIBC (RTOG 0233) Randomised Multicenter phase II Study

• Methods :

93 cT2-T4a patients recruited/ elegible from 2002-2008 in 24 US institutions

- Median Age 65
- Stage cT2 in 95% of the pts. cT3-T4 in 5%
- PS:0 in 90%, 1 in 10%
- Results : median F-up 5 yrs.
   5-yrs bladder intact survival: 65% in Paclitaxel group 71% in the Fluorouracil group



#### **RTOG 0233 Randomised Study on BP**


#### • Toxicity

P-Group : 34/40 pts. (85%) toxicity during adjuvant chemo F-Group: 19% Grade 3-4 toxicity in induction + 26% Grade 3-4 in consolidation + 11% Grade 3-4 after RT. Total toxicity : 56%. 1 patient died of toxicity in this group. Finally 13% and 6% of pts in P and F Group stopped treatment for toxicity



### Use of Molecular Markers in Bladder-Preservation Therapy: ASCO-GU 2018

- Lecture by Peter Hoskin (09.02.2018)
- Poster



#### **Translation of Biomedical Research Into Clinical Practice**

- RTOG investigated the outcome of 73 pts. treated in 4 bladder preserving protocols (overexpression of HER2)
- Results: In pts treated with TT the Overexpression of HER2 (ERBB2) correlated significantly with a reduced CR (50% vs 81% p= 0.026) (Chakravarti A et al Int J Rad Onc 2005)



DEPARTMENT OF UROLOGY Carpi - Modena , ITALY

### **Other Molecular Markers**

- MRE11 is one of the DNA damage –signaling proteins activated in the process of DNA double strand break repair (Meiotic REcombination 11 homolog)
- MRE11 espression was evaluated in MIBC pts. treated with definitive RT or RC
- Results: High MRE11 protein expression by the tumor predicted for improved outcome with RT but not by RC
- Conclusions: MRE11 overexpression is a predictive molecular marker of improved CSS after RT for MIBC (Choundury et al Cancer Res 2010)



#### **MRE11 and TIP60 in RC vs RT**

• The expression of MRE11 and Tat-Interactive protein 60 (TIP60) were evaluated in 435 pts who received RC in Denmark

#### • Results:

Elevated expression of TIP60 was significantly correlated with DSS in RC but not in RT pts. (opposite of MRE11)




#### **MRE11 and TIP60 in Combinations**


- TIP60 and MRE11 were used in combination in pts. who received RC or RT
- Results: low MRE11 expr + high TIP60 exp = better DSS in favour of RC (p=0.01) high MRE11 expr + low TIP60 expr = better DSS in favour of RT (p=0.012)
- Conclusions: MRE11 and TIP60 are interesting predicting markers. Need validation in prospective trials (Laurberg at al BJU Int 2012)




#### Genomic efforts identified intrinsic subtypes of MIBC that reflect breast cancer biology



#### MDACC: 3 molecular subtypes of MIBC






Validated in 3 independent cohorts.

Choi et al, Cancer Cell 2014

# **Molecular Subtypes**





Basal versus Luminal


- GSC, UNC, MDA, TCGA, Lund



 Basal tumors most sensitive to neoadjuvant chemotherapy


https://media.nature.com/full/natureassets/nrurol/journal/v11/n7/images/nrurol.2014.129-f2.jpg


# p53 pathway activation is associated with cisplatin resistance



MDACC Discovery (p=0.018)

MDACC Validation (p=0.014





#### Choi et al, Cancer Cell 2014

#### Trimodality Treatment of MIBC: ASCO-GU 2018 Results from lectures and Debates (Peter Hoskin 2018)

- Bladder sparing is offered more and more often in the US and Europe to patients with localised BC
- Tertiary centers should have protocols of bladder preservation to offer to their patients
- MDT in this setting is a must
- The Use of molecular markers to predict response (HER2, MRE11, TIP60, Molecular Subtypes, P-53 like) is the way but not ready yet in standard practice





#### Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy

David T. Miyamoto<sup>A</sup>, Ewan A. Gibb<sup>e</sup>, Kent W. Mouw<sup>c</sup>, Yang Liu<sup>e</sup>, Chin-Lee Wu<sup>A</sup>, Michael R. Drumm<sup>A</sup>, Johnathan Lehrer<sup>B</sup>, Hussam Al-Deen Ashab<sup>B</sup>, Nicholas Erho<sup>b</sup>, Marguerite du Plessis<sup>6</sup>, Kaye Ong<sup>6</sup>, William U. Shipley<sup>A</sup>, Elai Davicioni<sup>B</sup>, Jason A. Efstathiou<sup>A</sup>

<sup>4</sup>Massachuseits General Hospital, Boston, MA, USA, <sup>#</sup>Genome DX Biosciences Inc, Vancouver, Canada <sup>©</sup>Dana-Farber/Brigham & Women's Hospital, Boston, MA, USA

#### Background

Blackber-apartry conscioutly teacapy (TMT), consuming of transporting remarkers of the blackber brown (YUPBT) followed by chemicropolation, is no accordiants alternative to cystacherry for munchs sreasive therefor career (MED.) Chevanic proteing has demonstrated MREC can be divided into Provi or more entitypes with electricit responses in champingary, managemberg that (measure antidays) may tracked therapendic responses Harry, we sterilly percentic additions and support the time (equilities timoraed philicities) eendbriggs areas researching being and pictures an MINC patients transact with Disablar opaning transcality therapy




Figure 1: Molecular isolations constrained classes for MRD. (A) Molecular infrapola decrease five published anothers. (B) Tothernatic of the conservation inside infraod by the generate authyping consulter (CRC).

#### Materials and Methods

#### Milt Patient Cohnet

A tokal of 475 patients with sT2 T4a MIRC wave breated with blackter sparing TMT on promote as an per protocol at the Manuscrussette General receptor from 1005 to 2015 (median bituse-up 7.2 years). Of these 225 MINC patantia had fultilly mappy FFPE spectrums evolution for analysis. Transcriptions-wite game expression profiles were generated using Advinetria Homen Exon Array 1.0 IIT Hybridization. 139 samples passed ensurementary OC. Adulates and existing and any ensurementary of blacking convert person. same essensed for essention with overall and desense specific survival Transcriptorm-with differential expression analysis was used to explore gives not verticitement in bimodality function response groups

#### Mondal Devaloperatory

Description of the Double-regative model (DN sig) can be found in the

#### Grathadievel sumblements

Association of the double-respense (DN exp) consider with the time to carrier specific containsy was announced using the Rapize's Mean method and log same loss. Con proparticular bazzard mediat was used to perform univariable and multi-variable socion analysis with individual clinicopathylogic vieriations, inclusing age, geniller, clinical stages (7.2 vs. 7.3.74), matus of TURET (correlate vs. encorrelate), and hydriceseptensis. Elector analyses water also performed for the generative sublypring classifier (fields at al., first (Jeel 2016), country contact myratium (Swalls at at. Caroar Interacci Res. 2010), and instrumb of interlance gamma response (Liberror et al., Cell Byst 2015) The propertional leasantic mediat for the est-distribution of converting call (First and Gray, JASA 1990) was used to visualize the survival difference arrows solitypes after adjusting for descepations. war alien

Ngel (searc)	Nel CEL	e1.6
	StoriCe/V	
	20X You	27.4
	Mark Victories	3
Countries	a generates	ET (10.0%)
	access .	TES (708.00%)
	100	102791
	12	100 2/17 276 Y
The second second second	12	23122 782
Clinical diago	74	R (A DIA
	NA	-1 (St. P443
Nymmaphousia	442	X 549 (202 P.M.)
	124	201154.4757
	144	4 (2.4%)
	(ADDITION OF ADDITION OF ADDITIONO OF ADDITICO OF ADDITICO OF ADDITICO OF ADDITICO OF ADDITIC	0.3 pmp. 37%3
into Convepture PAINTEET	WHEN CHART	45 (12.4%)
	fee.	1.20.7763
TWT Response	stan-pickle Interpretable	240,000,005
	Antonio Charles Man Lauristee	-10.224.534
	Alah	2 (4.9%)
and the second second	- the	STREET 200 1988
allowyw Cyntrodeinay	ANA .	

	Contraction of the local division of the loc	-			
Outcon	tes by G	enor	nic Subty	pe	
^ 1=1	territori attante i second		e e		
HISSAI		11	1. 18. 19. 19		
MANNA.	ARM				
· The states	nde for de Destand	4!1 a.F	NUMBER OF STREET		
a for a set of the second s					
Variable	Meanificanting last	gewater.	Automatical service	provident .	
100	0.99 (0.96 4.93)	8.728	1.00 (0.97-3.04)	0.647	
Appropriate Access	0.88 (0.25 X MT)	2.467	H-MY (0.298-2.30)	0.003	
anapa > 12	3.66 (1.65-0.93)	0.000*	3.75 (1.30.10.80)	0.074*	
Technologian	IL & & DL R.Y. IS. HULL	0.002	4 21 10.89-5.79	0.735	
Annual Street Street	2.43 (1.07.4.48)	0.036-	181(0.64-8-15)	0.202	
Autor, Captornal on UK	0.86 (0.88 1.723	8.811	0.30105.895.3.397	0.125	
Larmost ve CL	0.95 (0.98 1.99)	0.134	0.21 (0.05-0.695	0.000	
Baust in Ch	0.82 (0.58-1.74)	0.291	0.2930.06-1.001	NUMP.	

#### Identification of double-negative / p53-like tumors in published datasets



Plaure 3: Generative profiles of karners with a thirddis-negative ( p02-bits (perception of an analysis) of the second se



Figure 4: Forced order heatmap identifying "double-negalive/p53-like" tumors within a separate cohort of 07 prospectively collected MIBC samples. Five brotogical categories (luminal, basal, immune, p53 and EMT) of selected MIBC marker pensa are indicated

For development of the double-negative / p53-like signature (DN-sig), 97 bladder cases from a separate prospective clinical cohort (CenomaDX) were clustered into 8 classes based on selected MBC marker genes. From Itia, a subset of tumors with high expression in p53, ECM, and EMT genes were identified with low expression of basel and luminal markers, but higher expression of immune, p53 and EMI genes. These cases were defined as "double-negative/p53-like". The genea were then grouped into modules via hierarchical clustering and the module averages were used as heatures for a GLMNET model to predict the "p53-like"





Figure 5: Regime Masse surves for disease specific survival (DSS) by "double negative/p53-sks' status. Patients with higher access have averag enformant at Bis observe mindon setting



ME TER TES

#### Figure 6

- (A) Kapian-Maier curves for CBM by INFy access. Patients with togher INF's activity have better CBM after chemoralitation
- (B) Bublyping by the GBC showing correlation of INFy score with generation aubtype
- (C) Kaplan-Maser curves for CBM by T-cell inflammation access Patients with higher T-cell inflammation have better CSM after cherocoscilation
- (D) Bubtyping by the GBC allowing correlation of T-cell inflammation score with genomic autotype.

100	th the gift that h hereig	4.454	1.00123-04-5.000	0.811
georder man	10.82 (0.88.0.00)	0.346	11.55-25-40-2.581	18.875
Miscor + TR	8410.234.798	Billion .	1.35 (0.86.4.1.9)	of states.
Principality, Photos P.	LEFTERIN-AME	B.CTS	X IN TO AN & AMI	8.855
Ingeneraptening	1.012530-4.FT	0.007	ARTIGAT AND	1.246
Mary + &* China	0.47-03.24.0.540	-2.515*	ware in cleaned	6.025*
Halfy + 5× Quar	0.47 (0.24.54)	-8-355*	A AN BE ZO IS AND MILLIO MADE CARDINE TAP	6.025*
And and a second se	Charleson and and	0.855	* 00 UK.08: 1 US	3.774
- Andrewson	0.30 (5.56 1.02) 0.37 (5.66 2.01)	4.855 8.765	CONTRACTOR OF THE	and the second se

Contraction of the local division of the loc	CARL ST MALE AND	- Martin	Place Margin Woods 1	arase
ALPHIAN.	3.007 (5 80-A.27)	8.087	1.35 (0.853.30)	0.82
A TH CLARE	0.4A 40.031.0.801	4.002	8.36 (0.17.0.76)	C.DOR*

#### Summary

- \* Transcriptome-ests gans expression profiling of MIEC revealed game sograshares correlated with response to blackler sparsey TMT
- \* In contrast to reconfluence characterapy provide radius cysta
- WTY, OXTAMOLEUM personnic subhypers dist net correlate with response to TMT \* A p\$3.5ke "double regains" apprature for among without basal or tassing
- marker expression was developed that absolution a subset of partnersh whether happe DOOR OLIFERMAN
- \* Transcruptureal algorithmus of increased Load enforcematics and IFNs algorithmy www.automated with improved disease specific survival
- Thusso reacits suggest the polasitist of pacterns profiling to pulde the test of placture-spacing threadship therapy for MIRC.

#### Acknowledgements

not in such his line his Tanis, Assault (1775), And, WARL for foremogen, Wellcome Four (2000), and

#### Asco-Gu 2018**5.** Francisco

### **Recent Clinical Studies**



DEPARTMENT OF UROLOGY Carpi - Modena , ITALY

### RC Compared to Combined Modality Treatment for MIBC: A Systematic Review and Metanalysis (2017)

- Metanalysis of 8 studies with about 9,000 pts
- Results: No difference in OS , DSS
- Limitations
  - \* Retrospective studies
  - \* A consistent N of pts. Underwent salvage RC in the majority of the studies
  - \* Chemotherapy was not always used
  - \* Selection bias: pts receiving RT were older with more co-morbidities \* (Vashistha et al Int J Rad Onc. 2017)



### Propensity Score Analysis of RC vs TMT in the Setting of a Multidisciplinary BC Clinic (Kulkarni et al J Clin Onc 2017)

- Retrospective study including 112 patients: RC : 56 TMT : 56 Statistical Method: Propensity Score Analysis to reduce at minimum the differences between the 2 groups
- Patients were stratifies according to: TURBT, T stage, IDN, Cis and co-morbidities
- **Results:** NO diffeence in OS and DSS



EURURO-7185; No. of Pages 9

#### ARTICLE IN PRESS

available at www.sciencedirect.com journal homepage: www.europeanurology.com





Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience

Nicholas J. Giacalone<sup>a,b</sup>, William U. Shipley<sup>a</sup>, Rebecca H. Clayman<sup>a</sup>, Andrzej Niemierko<sup>a</sup>, Michael Drumm<sup>a</sup>, Niall M. Heney<sup>c</sup>, Marc D. Michaelson<sup>d</sup>, Richard J. Lee<sup>d</sup>, Philip J. Saylor<sup>d</sup>, Matthew F. Wszolek<sup>c</sup>, Adam S. Feldman<sup>c</sup>, Douglas M. Dahl<sup>c</sup>, Anthony L. Zietman<sup>a</sup>, Jason A. Efstathiou<sup>a,\*</sup>

<sup>a</sup>Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; <sup>b</sup>Harvard Radiation Oncology Program, Boston, MA, USA; <sup>c</sup>Department of Urology, Massachusetts General Hospital, Boston, MA, USA; <sup>d</sup>Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

Article info	Abstract						
Article history: Accepted December 21, 2016	Background: Tri-modality therapy (TMT) is a recognized treatment strategy for selected patients with muscle-invasive bladder cancer (MIBC). Objective: Report long-term outcomes of patients with MIBC treated by TMT.						
Associate Editor: Giacomo Novara	Design, setting, and participants: Four hundred and seventy-five patients with cT2-T4a MIBC were enrolled on protocols or treated as per protocol at the Massachusetts General Hospital between 1986 and 2013.						
Keywords: Bladder cancer	Intervention: Patients underwent transurethral resection of bladder tumor followed by concurrent radiation and chemotherapy. Patients with less than a complete response (CR, to chemoradiation or with an invasive recurrence were recommended to undergo salvage radical cystectomy.						
Radiation therapy Chemotherapy	Outcome measurements and statistical analysis: Disease-specific survival (DSS) and over- all survival (OS) were calculated using the Kaplan-Meier method.						
Tri-modality therapy	Results and limitations: Median follow-up for surviving patients was 7.21 yr. Five- and 10-yr DSS rates were 66% and 59%, respectively. Five- and 10-yr OS rates were 57% and 39% respectively. The risk of salvage cystectomy at 5 yr was 29%. In multivariate analyses, T2 disease (OS hazard ratio [HR]: 0.57, 95% confidence interval [C1]: 0.44–0.75, DSS HR: 0.51 95% C1: 0.34–0.73), CR to chemoradiation (OS HR: 0.61, 95% C1: 0.44–0.75, DSS HR: 1.56, 95% C1: 0.34–0.71), and presence of tumor-associated carcinoma in situ (OS HR: 1.56, 95% C1: 1.17–2.08, DSS HR: 1.50, 95% C1: 1.03–2.17) were significant predictors for OS and DSS When evaluating our cohort over treatment eras, rates of CR improved from 66% to 88% and 5-yr DSS improved from 60% to 84% during the eras of 1986–1995 to 2005–2013, while the 5-yr risk of salvage radical cystectomy rate decreased from 42% to 16%. Conclusions: These data demonstrate high rates of CR and bladder preservation in patients receiving TMT, and confirm DSS rates similar to modern cystectomy series. Contemporary results are particularly encouraging, and therefore TMT should be discussed and offered as a treatment option for selected patients. Patient summary: Tri-modality therapy is an alternative to radical cystectomy for patients with muscle-invasive bladder preservation. © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved						
	* Corresponding author. Department of Radiation Oncology, Massachusetts General Hospital 100 Blossom Street, Cox 3, Boston, MA 02114-2606, USA. Tel. +1 617 726 5866; Fax: +1 617 726 3603						

E-mail address: jefstathiou@partners.org (I.A. Efstathiou).

http://dx.doi.org/10.1016/j.eururo.2016.12.020 0302-2838/⊕ 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Please cite this article in press as: Giacalone NJ, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2016.12.020  475 pts. with T2-T4a BC enrolled in MGH between 1986 to 2013.
 Methods: TURBT + RT and Chemo CR: re-TUR and F-UP No CR : Cystectomy

*Results:* (median F-Up 7.21 yrs)
. 5-yr DSS = 66% 10-yr DSS = 59%
. 5-yr OS = 57% 10-yr OS = 39%
RC rate at 5-yr = 29%
Multivariate analysis: *T2, CR to C/RT*, *Cis predictors for OS- DSS*'86-'95 5-yr DSS = 60% vs 84% '00-'13
5-yr risk of Salvage RC
'86-'95 = 42% vs 16% '00-'13

#### • Conclusions:

TMT should be discussed and offered to selected pts. with MIBC as treatment option

### EAU Guideline 2017. Multimodality Treatment

- «Offer multimodality treatment as an alternative in selected, well informed and compliant patients, especially for whom cystectomy is not an option»
- In highly selected patient population, long-term survival rates of multimodality treatment are comparable to those of early cystectomy. Delay in surgical therapy can compromise survival rates
- .... Costs of TMT vs RC ??

# **European Association of Urology**

#### Radical Cystectomy Provides Improved Survival Outcomes and Decreased Costs Compared With Trimodal Therapy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer

Stephen B. Williams<sup>1</sup>, William Tabayoyong<sup>2</sup>, Yong Shan<sup>1</sup>, Usama Jazzar<sup>1</sup>, Hemalkumar B. Mehta<sup>3</sup>, Jacques G. Baillargeon<sup>4</sup>, utmb Health Jinhai Huo<sup>5</sup>, Anthony J. Senagore<sup>3</sup>, Eduardo Orihuela<sup>1</sup>, Douglas S. Tyler<sup>3</sup>, Todd A. Swanson<sup>6</sup>, Ashish M. Kamat<sup>2</sup>

From the The Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX1; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX2; Department of Surgery, The University of Texas Medical Branch at Galveston, TX<sup>4</sup>, Department of Medicine, Division of Epidemiology, Sealy Center on Aging, The University of Texas Medical Branch at Galveston, TX<sup>4</sup>, Department of Health Services Research Management and Policy, The University of Florida, Galveston, TX<sup>4</sup>

#### Purpose

Recently there has been a resurgence in trimodal 'bladder sparing' therapy with limited data on comparative outcomes, and especially attributable costs Given the lack of population-based studies with cost valuations and cancerspecific survival outcomes, we examined a nationally representative cohort to evaluate overall and cancer-specific survival outcomes as well as costs of treatment.

#### Background

There will be an estimated 79,030 new cases and 16,870 deaths from bladder cancer in the United States in 2017.1

Neoadiuvant chemotherapy followed by radical cystectomy with extended pelvic lymphadenectomy is the guideline recommended treatment for patients with muscle-invasive bladder cancer.2-4

There has been an increase in use of less invasive trimodal 'bladder-sparing' approaches using a combination of maximal transurethral resection. chemotherapy and radiotherapy for muscle-invasive bladder cancer.5

The European Association of Urology, National Comprehensive Cancer Network and the American Urological Association have updated guidelines supporting the use of radiotherapy combined with chemotherapy in select patients with muscle-invasive disease 28.7

While no randomized data exists comparing trimodal therapy to radical cystectomy, two single center studies limited by small numbers of patients have noted comparable survival outcomes.<sup>8,9</sup> Moreover, while costs of radical cystectomy have been previously assessed.<sup>10</sup> trimodal therapy costs and trends have not been directly compared to radical cystectomy.

#### Methods

A total of 3.200 petients aged 66 years or older diagnosed with clinical stage T2-4a bladder cancer from January 1, 2002-December 31, 2011 from the Surveillance: Epidemiclogy, and End Results (SEER)-Medicare data were


Procedure codes were used to identify radical cystectomy patients, and Medicare claims indicating recept of both radiation and chemotherapy following transpretival resection of the bladder without a radical cystectomy were used to identify trimodial therapy patients.

Propensity score matching was used to adjust for differences in baseline climital and demographic characteristics between patients receiving trimodal therapy versus radics cyntectoms

To petermine treatment costs, we summed all Medicare healthcare expenditures from incellent, outpatient, and physician services within 30, 90

setup THE dames of transferreet

other Designation of the local division in which the local division in which the local division is not the local division of the local division in the loc	the second value of the se	and the owner where the party is not	-	and the owner of the	-	-				
		-	Test.	-				-		-
	-		-		-	30.05			1 1	
and the second se	200	100	81	- 10	.202		æ	353	47 50	
and the second se	-	-	-	-		4.05	- 100		10 100	-
	-	-	-	- 24	2004	4.75		100	27 .005	-
	-	and in	200	-	3		-	100	20. 20.0	-
·	-		344	34.	-0.9	1.000	218	10.1	30. 411	-
The Real Property lies in the Party name						1.07				
and the second second second	-	-	10.0	-			-	-		
		100	-	-	202	-	-	- 200	20 201	
	-	- 22.00	100	-	-	1000	-		-10. 00	-
the state of the s	-	100		12.	-	94751		-	2 40	- 10
			- 100					-		-
	*	-					-			
	-	-	-	315		-42.029	-	-	A 30	-
	-	100	6.2	-107	107	-		200	78 251	-
the second s	-	-		1.000	10.0		. 34	. 304	187 267	-
the second s		-		-				-	-	
	-	-	-	-			-	-	-	
and the second se	1	-	1.2	-	-		-		-	
	-	-	-	-		-				-
and the second se										
and the second se	100	- 10	210	-24	214	240	-	100	27 207	
COLOR DALLA	-	. 426	254	325	224		-	200	Jan 200	
and the second		-	100	-	200	-	25	-		-
Carlos and the second se	-	- 550	200	-		1000	100	309	100 300	-
	-	-		-	24		-		-	
	-	-	-	-		-		-		
and the second second	2	-		-	-	1.00		-		-
	1.2	-	-	- 14		-	-			-
				-						
	100	100	344	-	-	-	-	100	-	100
	100	-	and the	24	gen.	-	-	- 944		
Contraction of the local division of the loc	1.00	34	100	- 20	-	100	-	-	- ME	
		-					-		7 25	
A DESCRIPTION OF TAXABLE PARTY.	-	-	946	-		100	-	100	-	-
	1	-	100	-			-	-	-	-
	-			-			-		100 100	-
								-		
the local distance in the local distance in the	-	-		-	-		-	-	-	-
	-		-				-		* *	
and the second division of the second divisio									-	
	1	-		-	-		-			200
	100	-		-		1000	-	-		-
	1	-		-		-	-	100	-	-
-	-	-	-	-	200	-	*		B. 200	
	-	100	100	100	-	-	-	100	10 ML	1
		-		-	100		-			
	2	- 20	-	2	140			- 100	-	-
	1000	-	-						THE R. LANS.	1.00





#### Results

Propensity score matching resulted in 687 trimodal therapy and 687 radical cystectomy patients. Patients who underwent trimodal therapy had significantly decreased overall (Hazard Ratio (HR) 1 49, 95% Confidence Interval (CI), 1.31-1.69, p<0.001) and cancer-specific (HR 1.55, 95% Cl 1.32-1.83, p<0.001) survival, respectively.

There was no difference in annual median 30-day health care costs between trimodal therapy and radical cystectomy. However, median total costs were significantly higher with trimodal therapy than radical cystectomy at 90-d (\$63,355 vs. \$73,420, p<0.001) and 180-d (\$98,005 vs. \$164,720, p<0.001), respectively.

#### Conclusion

Trimodal therapy was associated with significantly decreased overall and cancer-specific sunival at increased costs compared with radical cystectomy. Extrapolating these figures to the total US population results in excess spending of \$179 million for trimodal therapy compared to less costly radical cystectomy for sed OS and DSS

#### Asco-GU 2018

#### with TMT and

patients who are candidates for either treatment.

#### References

- Suppl. R., Miler KD. Jersel A. Cancer Hallings, 2017 Ch. Denser J. Co. 2017 67 7-30.

- the figure constants on Lanta president in mathematics and the second
- present design in the Real Property lines a Property Property of the

# **Conclusions**

- Treatment for localized BC should be decided according to prognostic factors (clinical, pathological and biomolecular)
- Neoadjuvant chemo (cisplatin based) + RC and extended LND performed by an experienced surgeons in a high volume institution remains the golden standard treatment. (Brausi ... Esou 2018)



### **Conclusions**

BP is recommended only in selected, well informed and compliant pts in whom RC is not considered for clinical or personal reasons.

A T0 status after the first TUR or Chemo is a prognostic positive variable

Tur alone or chemo alone are not recommended as primary treatment of localized BC for BP strategy A multimodality treatment (Tur + Chemo or RT, TUR+ RT + Chemo) is the best choice



### **Conclusions : Factors Associated with BP**

- 1. Clinical Stage (pT2)
- 2. Tumor size (<3-5 cm)
- 3. Absence of Hydronephrosis
- 4. Absence of palpable mass after TUR
- 5. Unifocal Disease, NO CIS
- 6. Downstaging to PT0 after chemo + TUR : the best



### CLINICAL CASE

65-yr old pt. with 3 solid tumors.

02.18 TURBT + Bladder mapping. Path report: T1cHGTcc No Cis. LVI. DM present with 1 focus of Tcc in the DM

What do you suggest ?



# **Bladder Cancer : The Future**

- The Cancer Genomic Atlas :
- Is a collaborative project between the NCI and NHGRI. TCGA has generated comprehensive maps of key genomic changes in 33 different type of cancer including 10 rare tumours.
- TCGA is really an example of multidisciplinary research Goal: to create an atlas of genomic changes using an integrated multiplatform analysis and have all the data available in the public domain for researchers worlwide to use

# The Cancer Genomic Atlas : MIBC

- TCGA has resulted in discovery of novel cancer mutation and better understanding of pathways and mechanisms involved in cancer development.
- In a group of 412 MIBC mutational changes were found in 58 genes. A high-mutation subset with a 5-year survival rate of 75% was identify by mutation signature clustering, whereas mRNA expression clustering yelded 5 expression-based sub-types that were associated with OS and may explain response to treatment.

# The Cancer Genomic Atlas: MIBC

- The research provided a more precise definition of expression-based molecular subtypes and mutation signature-based subtypes. This has implications from the biological standpoint and potentially from the therapeutic standpoint by affecting the response to chemotherapy and immuno-oncology agents
- Another finding was that mRNA and long noncoding RNA further modify the expression based subtypes

# **The Cancer Genomic Atlas**

- There are important questions that still need to be answered:
  1. How do we take TCGA findings into the clinic and apply them to other patient population. Are these findings truly generalizable?
  2. How do we take next-generation sequencing into the clinic so that we can use them in a user-friendly way?
- The very final goal is to arrive a precision medicine-based aproach to treating invasive bladder *Lerner Set Baylor College ASCO-GU 2018*

# Materiale

- Genome
- UUTcc
- Multimodality Treatment of MIBC
- Immunotherapy in MIBC

# **Biomarkers in MIBC**

- Biomarkers for selecting patients who undergo chemotherapy before cystectomy
- Basal cell sub-type and Luminal cell sub-Type
- Basal cell sub-type tumors have more benefit from adjuvant chemo
- NOXEN model predict response to NAC in individual patients
- Alteration in DNA repair genes may define patients who will likely to respond *Peter Black Canada ASCO-GU 2018*

## **Check Point Inhibitors in Urothelial TCC**

- Check point-Inhibitors determine 20- 25% RR in metastatic disease
- Indications : \* Metastatic disease (second line after chemo)
   \* Cis-Platinum inelegible patients or Platinum refractory disease (first line)
- *PEMBROLIZUMAB* the only one that showed efficacy vs chemo in randomised-prospective study (Bellmunt et al NEJM 2016)
- Atezolizumab (neg in bladder),.....Nivolumab, Durvalumab, Avelumab, *Pembrolizumab*
- PD-L1
- Biomarkers : not useful

# NMIBC

- Two important studies design on immunotherapy :
- 1. ALT-803 + BCG vs BCG alone in high risk Tcc of the bladder
- 2. A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive NMIBC

# **RTOG Protocol 0524: Phase I/II In Pts with MIBC Not fit for Surgery**

- Daily RT + weekly Paclitaxel and the HER2 targeted ab Trastuzumab given to pts. whose tumors overexpress HER2.
- 70 patients recruited : results still pending (Mitin et al Curr Urol Rep 2013)



DEPARTMENT OF UROLOGY Carpi - Modena , ITALY

### Genetic Alterations Predicting Response to Chemotherapy

- ERBB2 mutations characterize a subgroup of muscle invasive bladder cancers with excellent response to neo-adjuvant chemotherapy Groenendijk FH et al Eur Urol 2016;69:384
- Alterations in ATM, RB1 and FANCC correlates with survival after NAC Van Allen, Cancer Discov 2014, Plimack, Eur Urol 2015






Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

Elizabeth R. Plimack<sup>a,\*</sup>, Roland L. Dunbrack<sup>\*</sup>, Timothy A. Brennan<sup>b</sup>, Mark D. Andrake<sup>a</sup>, Yan Zhou<sup>\*</sup>, Ilya G. Serebriiskii<sup>\*</sup>, Michael Silfer<sup>\*</sup>, Katherine Alpaugh<sup>\*</sup>, Essel Dulaimi<sup>\*</sup>, Norma Palma<sup>\*</sup>, Jean Hoffman-Censits<sup>\*</sup>, Marijo Bilusic<sup>\*</sup>, Yu-Ning Wong<sup>\*</sup>, Alexander Kutikov<sup>\*</sup>, Rosalia Viterbo<sup>\*</sup>, Richard E. Greenberg<sup>\*</sup>, David Y.T. Chen<sup>®</sup>, Costas D. Lallas<sup>\*</sup>, Edouard J. Trabulsi<sup>\*</sup>, Roman Yelensky<sup>\*</sup>, David J. McConkey<sup>\*</sup>, Vincent A. Miller<sup>\*</sup>, Erica A. Golemis<sup>®</sup>, Eric A. Ross<sup>\*</sup>

\*Fox Chase Cancer Center, Philadelphia, PM, USA; <sup>b</sup>Foundation Medicine Inc., Cambridge, MA, USA; <sup>c</sup>Thomas Jefferson University Hospital, Philadelphia, PA, USA; <sup>d</sup> MD Anderson Cancer Center, Houston, TX, USA

Platinum Priority – Urothelial Cancer Editorial by XXX on pp. x-y of this issue

#### Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy



Seiler et al., Eur Urol. 2017 Apr 5.]

# Bladder Spaing Approach : Review of the Literature (Ploussard et al Eur Urol 2014)

- TUR BT + RT + Chemo (most used)
- Dose of Radiotherapy : varies
- Type of Chemotherapy: Should be cisplatin based

### **Bladder Sparing Trimodality Treatment** (Efstathiou et al Eur Urol 2012)

- Bladder Sparing Trimodality Approach: Maximal TURBT + RT (40Gy) and concurrent Chemo (Cisplatin based): Re-TURBT and Assessment of Response
- Incomplete Response = Radical Cystectomy
- Complete Response = Chemo + RT to 65 Gy
- Single Institutions in North America and Europe + multiinstitutional studies enrolled > 1200 pts with MIBC in bladder preserving protocols



### **Bladder Sparing Trimodality Treatment** (Efstathiou et al Eur Urol 2012)

- Material and methods: 348 pts. treated from'86 to 2006. Up-dated F-Up : 7.7 yrs
- Results: CR = 72% (to induction therapy). 102/348 pts (29%) had salvage RC (60: IR, 42 Recurrent Invasive T)
  5 yr- DSS = 64%, 10yr-DSS = 59%, 15yr-DSS = 57%
  5-yr- OS = 52%, 35%, 22%.
  In CRs the Recurrence rate at 10 years was: 29% (NMIBC),16% (MIC), Recurrence rate: Pelvic recurrence (11%) Distant mets (32%)
  In patients who had visibly complete TURBT 22% required RC vs 42% incomplete TURBT (p< 0.001)</li>



## **Bladder Sparing Trimodality Treatment**

### • Conclusions:

In long term F-UP, selective BP trimodality therapy is associated with a high rate (71%) of BP and OS rate comparable to that in contemporary RC. (Efstathiou et al Eur Urol 2012)

